News
Feed
Events
Feed
News
+ Events
Feed

PreveCeutical Medical Inc.

  • ISIN CA74141E1043

Aktuelle News

4 Mai 2020

19:37 Corporate EN

PreveCeutical Medical Inc.

Corporate
EN

PreveCeutical Announces Possible Viral Prevention Program Using CBD Sol-gel

23 Januar 2020

14:00 Corporate EN

PreveCeutical Medical Inc.

Corporate
EN

PreveCeutical Retains Patent Legal Team

14 Januar 2020

14:00 Corporate EN

PreveCeutical Medical Inc.

Corporate
EN

PreveCeutical Announces Further Updates to the Successful Engineering & Cell-Based Efficacy Screening of its Smart-siRNA Constructs for its Dual Gene Therapy Research Program

8 Januar 2020

14:00 Corporate EN

PreveCeutical Medical Inc.

Corporate
EN

PreveCeutical Announces Positive Results Following a Preliminary Safety Evaluation of Sol-Gel Formulations When Applied to Human Nasal Tissue

29 Oktober 2019

15:35 Corporate EN

PreveCeutical Medical Inc.

Corporate
EN

PreveCeutical Announces Successful Completion from its Design, Synthesis and Preliminary Evaluation of Novel Designed Peptides Derived from Caribbean Blue Scorpion Venom in a Cell-Based Brain Cancer Model

7 Oktober 2019

14:04 Corporate EN

PreveCeutical Medical Inc.

Corporate
EN

PreveCeutical Receives $616,802 AUD Research and Development Tax Incentive Cash Refund

23 September 2019

14:03 Corporate EN

PreveCeutical Medical Inc.

Corporate
EN

PreveCeutical Announces the Successful Engineering & Cell-Based Efficacy Screening of its Smart-siRNA Constructs for its Dual Gene Therapy Research Program

3 September 2019

14:03 Corporate EN

PreveCeutical Medical Inc.

Corporate
EN

PreveCeutical Reaches Milestone in Research Program for Development of Non-Addictive Analgesics

6 August 2019

21:19 Corporate EN

PreveCeutical Medical Inc.

Corporate
EN

PreveCeutical Grants Asterion Option to Purchase up to a 51% Interest in Sol-Gel Intellectual Property

20:02 Corporate EN

PreveCeutical Medical Inc.

Corporate
EN

PreveCeutical Grants Asterion Option to Purchase up to a 51% Interest in Sol-Gel Intellectual Property

9 Juli 2019

14:03 Corporate EN

PreveCeutical Medical Inc.

Corporate
EN

PreveCeutical Successfully Incorporates Medicinal Cannabis Extracts into the Sol-Gel Drug Delivery System

17 Juni 2019

14:03 Corporate EN

PreveCeutical Medical Inc.

Corporate
EN

PreveCeutical Announces Further Positive Results from its Dual Gene Therapy Research Program

3 Juni 2019

14:03 Corporate EN

PreveCeutical Medical Inc.

Corporate
EN

PreveCeutical Secures $300,000 Loan and Resignation of a Director

21 Mai 2019

14:02 Corporate EN

PreveCeutical Medical Inc.

Corporate
EN

PreveCeutical Granted Approval to Acquire and Use Human Mucosal Tissue for Final Phase of Sol-Gel Program

17 April 2019

16:37 Corporate EN

PreveCeutical Medical Inc.

Corporate
EN

PreveCeutical Partnership Leads to Two New Patent Filings

15 April 2019

14:32 Corporate EN

PreveCeutical Medical Inc.

Corporate
EN

PreveCeutical Files Application to Human Ethics Committee to Acquire Human Tissue for the Final Phase of the Sol-Gel Program

10 April 2019

14:32 Corporate EN

PreveCeutical Medical Inc.

Corporate
EN

PreveCeutical Announces Further Results from its Preliminary Screening of Peptides Derived from Blue Scorpion Venom in a Cell-Based Brain Cancer Model

8 April 2019

15:37 Corporate EN

PreveCeutical Medical Inc.

Corporate
EN

PreveCeutical Announces Default Judgment Against JCN Capital Corp.

4 April 2019

20:42 Corporate EN

PreveCeutical Medical Inc.

Corporate
EN

Asterion Welcomes Australian Government Awarding of Major Project Status for its Toowoomba Medicinal Cannabis Project

20:42 Corporate EN

PreveCeutical Medical Inc.

Corporate
EN

Asterion Welcomes Australian Government Awarding of Major Project Status for its Toowoomba Medicinal Cannabis Project

25 März 2019

13:01 Corporate EN

PreveCeutical Medical Inc.

Corporate
EN

PreveCeutical Announces Default Judgment Against Essos Corporate Services Inc. and Detona Capital Corp.

11 März 2019

14:01 Corporate EN

PreveCeutical Medical Inc.

Corporate
EN

PreveCeutical Announces Preliminary Screening Results of Peptides Derived From Blue Scorpion Venom in a Cell-Based Brain Cancer Model

13 Februar 2019

14:31 Corporate EN

PreveCeutical Medical Inc.

Corporate
EN

PreveCeutical Announces Appointment of Dr. Makarand Jawadekar as President

29 Januar 2019

14:01 Corporate EN

PreveCeutical Medical Inc.

Corporate
EN

PreveCeutical to Explore Partnerships with Pharmaceutical and Biotechnology Companies for the Co-Development of its Sol-Gel System

14 Januar 2019

14:31 Corporate EN

PreveCeutical Medical Inc.

Corporate
EN

PreveCeutical Provides Update on the Dual Gene Therapy Program

8 Januar 2019

14:31 Corporate EN

PreveCeutical Medical Inc.

Corporate
EN

PreveCeutical Provides Update on Research Program for Development of Non-Addictive Analgesics

7 Januar 2019

15:00 Corporate EN

PreveCeutical Medical Inc.

Corporate
EN

PreveCeutical Files Notice of Civil Claim Against the BridgeMark Group

20 November 2018

15:01 Corporate EN

PreveCeutical Medical Inc.

Corporate
EN

PreveCeutical Converts Acidic Phytocannabinoids to Neutral Form and Doubles Contents of Fingerprinted Cannabis Extract Library

19 November 2018

13:01 Corporate EN

PreveCeutical Medical Inc.

Corporate
EN

PreveCeutical Confirms Encouraging Results from Sol-gel Applicator Trials for Achieving Direct Nose-to-Brain Delivery in an Adult Human Nasal Cast

13 November 2018

15:01 Corporate EN

PreveCeutical Medical Inc.

Corporate
EN

PreveCeutical Announces LOI with Crushedit LLC to Supply CBD Isolate for Expected Sale Proceeds of $16.25 Million

Anstehende Events

Keine Events gefunden